课题基金 / 基金详情

Fibroblast Differentiation During Eye Development

Fibroblast Differentiation During Eye Development
眼睛发育过程中成纤维细胞分化
批准号:
8244493
负责人:
GARY W CONRAD
金额:
$35.16万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1988
资助国家:
美国
项目状态:
已结题
起止时间:
1988-08-01 至 2014-03-31

项目摘要

项目成果

GARY W CONRAD的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The long-range goal of the proposed research is to understand the biological physical chemistry of the corneal extracellular matrix (ECM) during embryonic development and be able to repair that ECM in adults. This is of immediate medical importance for two reasons: 1) In the U.S. alone, several million patients have undergone LASIK. LASIK manipulations of the cornea create a transparent, but permanently non-attached stromal flap. LASIK also significantly reduces corneal innervation, and can greatly increase perceived Dry Eye. In the general population, Dry Eye affects 11% of people over 30 and 15% of people over 65, and has been linked to corneal neuropathy. Proteoglycans of the LASIK scar interface are abnormal compared with adjacent stroma. Existing non-attached LASIK flaps are of concern for their physical instability during facial trauma. Herein, we develop methods to reduce that instability by chemically crosslinking normal and abnormal stromal ECM components, and assess gene expression in adjacent corneal stroma fibroblasts (keratocytes), Schwann cells, and nerves. 2) Another clinically important physical manipulation of corneal ECM, combined riboflavin and ultraviolet light (UVA) administration, has begun trials in the U.S. as a treatment for keratoconus. This treatment alters corneal ECM by mechanisms assumed, but not yet proven, to involve collagen crosslinking, with proteoglycan involvement. Resulting regeneration and wound healing reactions of surrounding surviving corneal nerves and keratocytes involve cellular migrations within the stroma and changes in keratocyte and nerve differentiated states yet to be characterized. Here, we begin a study of the biological physical chemistry of the corneal ECM, characterizing the molecular biology of the ECM macromolecules synthesized normally and also in response to clinical treatments. Proteomic and glycomic microarrays will be used to determine physical binding specificities of ECM molecules. Laser Capture Microdissection, MALDI-TOF/TOF and other mass spectrometry techniques will be used for detailed analyses that can detect changes in very restricted corneal ECM regions and cell populations following LASIK and riboflavin+UVA treatments, as well as after other clinically important corneal procedures and conditions, e.g., LASEK, PRK, corneal transplantation, and Dry Eye. Specific Aims: 1) Determine chemical mechanisms by which riboflavin+UVA treatment cross-links the corneal stroma and affects corneal cells, and thereby devise chemical mechanisms for covalently immobilizing LASIK flaps. 2) Use glycomic and proteomic microarrays and surface plasmon resonance assays to determine binding preferences and association and dissociation kinetics of corneal proteoglycans for neurotrophins, growth factors, neurotransmitters, hormones, and structural macromolecules of the cornea. 3) Characterize gene expression in trigeminal neural crest-derived nerves and in their non-myelinating Schwann cells following neuronal growth cone contact with keratan sulfate (KS) and with KS-proteoglycan core proteins. PUBLIC HEALTH RELEVANCE: The cornea is the only living tissue in the body that is both transparent and highly innervated with sensory nerve endings, meaning that any medical treatment of the cornea, elective or required, has the potential for permanently damaging sight and producing great pain. The long-range goal of the proposed research is to understand and to learn to repair the connective tissue of the cornea of the eye, based upon lessons learned from studying the differentiation of the connective tissue fibroblasts of the corneal stroma (the "keratocytes") during embryonic development and in adults. This is of immediate medical public health importance, first, because the most currently popular elective eye surgery, LASIK, produces corneas that, while transparent in most patients, never truly heal and become problematic in 2-3% of patients, and, second, because an exciting new treatment involving riboflavin (vitamin B2) and long wavelength-ultraviolet light (UVA) has been devised whose primary mechanism and potential side effects remain unknown, but whose remarkable primary effect of "toughening" the cornea greatly slows the rate at which a very serious, progressive syndrome, keratoconus, makes corneas thin, cone-shaped, and perforated, and could provide a mechanism for "healing" LASIK corneas.
期刊论文(74)
专著(0)
科研奖励(0)
会议论文
Pretreatment methods to improve nerve immunostaining in corneas from long-term fixed embryonic quail eyes.
改善长期固定胚胎鹌鹑眼角膜神经免疫染色的预处理方法。
DOI: 10.1016/s0165-0270(99)00109-0
发表时间: 1999
期刊: Journal of neuroscience methods
影响因子: 3
作者: [Barrett,JE, Wells,DC, Conrad,GW]
通讯作者: Conrad,GW
Identification and characterization of conserved cis-regulatory elements in the human keratocan gene promoter.
人角蛋白基因启动子中保守顺式调控元件的鉴定和表征。
DOI: 10.1016/s0167-4781(00)00129-9
发表时间: 2000
期刊: Biochimica et biophysica acta
影响因子: --
作者: [Tasheva,ES, Conrad,AH, Conrad,GW]
通讯作者: Conrad,GW
DOI: 10.1016/s0021-9258(18)60856-7
发表时间: 1987-08
期刊: The Journal of biological chemistry
影响因子: --
作者: [J. Funderburgh;B. Caterson;G. Conrad]
通讯作者: J. Funderburgh;B. Caterson;G. Conrad
DOI: --
发表时间: 1988-07
期刊: Investigative ophthalmology & visual science
影响因子: 4.4
作者: [J. Funderburgh;C. Cintron;H. Covington;G. Conrad]
通讯作者: J. Funderburgh;C. Cintron;H. Covington;G. Conrad
47
    Transcriptional Regulation of Keratocan and Mimecan
    • 批准号:
      6317076
    • 项目类别:
    • 资助金额:
      $31.51万
    • 财政年份:
      2001
    • 负责人:
      GARY W CONRAD
    • 依托单位:
    Transcriptional Regulation of Keratocan and Mimecan
    • 批准号:
      6604327
    • 项目类别:
    • 资助金额:
      $25.37万
    • 财政年份:
      2001
    • 负责人:
      GARY W CONRAD
    • 依托单位:
    Transcriptional Regulation of Keratocan and Mimecan
    • 批准号:
      6518715
    • 项目类别:
    • 资助金额:
      $25.37万
    • 财政年份:
      2001
    • 负责人:
      GARY W CONRAD
    • 依托单位:
    Transcriptional Regulation of Keratocan and Mimecan
    • 批准号:
      6759979
    • 项目类别:
    • 资助金额:
      $25.37万
    • 财政年份:
      2001
    • 负责人:
      GARY W CONRAD
    • 依托单位:
    海外基金